Keywords: GlaxoSmithKline, Human Genome Sciences, Benlysta, FDA, PDUFA, Lupus

GlaxoSmithKline/Human Genome’s Benlysta delayed, as US FDA pushes back PDUFA target

Article | 06 December 2010

Print This

UK pharmaceutical giant GlaxoSmithKline (LSE: GSK) and the USA’s Human Genome Sciences (Nasdaq: HGSI) revealed on Friday that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in